Life Science Hour Seminar Series

Name:Dan Stinchcomb
 Chief Science Officer. Infectious Disease Research Institute.
Title:Developing vaccines for mosquito-borne viral diseases
Date:Friday, 3 March 2017
Location:Murie Life Science Bldg, Murie Auditorium.

About the Speaker:

Dan Stinchcomb has over 25 years of biotechnology experience. As Chief Scientific Officer at the Infectious Disease Research Institution, he is focusing on developing lower cost vaccines, diagnostics and therapeutics for infectious disease threats worldwide. Prior to joining IDRI, he was President of Global H, LLC and co-founder and Chief Executive Officer of Inviragen, Inc. Under his leadership, Inviragen grew from a start-up to a global clinical stage company. Inviragen advanced vaccines for dengue fever and hand, foot and mouth disease from research to proof-of- concept human clinical trials and developed several vaccine candidates through advanced preclinical testing. He completed numerous partnerships and collaborations, executed a merger with an Asian vaccine company, and raised over $30 million in grants and contracts and over $30 million in equity financing. Inviragen was acquired by Takeda Pharmaceuticals in 2013. Prior to co-founding Inviragen, he held senior scientific management positions at Heska Corp., Ribozyme Pharmaceuticals, Inc., and Synergen, Inc. He started his career as an Assistant and Associate Professor in Cellular and Developmental Biology at Harvard University and post-doctoral fellow at University of Colorado. He holds a PhD from Stanford University and BA from Harvard College.

Life Science Hour Seminars

Academic Year